Skip to main content
. 2022 May 20;6(10):3114–3125. doi: 10.1182/bloodadvances.2022007017

Figure 4.

Figure 4.

Cost-effectiveness acceptability curve of fondaparinux and rivaroxaban compared with argatroban.